1.3800
-0.1100
(-7.38%)
At close: April 3 at 4:00:02 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.75 | -0.79 | -3.24 | -3.23 |
| Low Estimate | -0.79 | -0.83 | -3.44 | -3.82 |
| High Estimate | -0.68 | -0.76 | -3.13 | -2.66 |
| Year Ago EPS | -12.27 | -0.77 | -3.85 | -3.24 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.45 | -0.81 | -0.74 | -0.79 |
| EPS Actual | -12.27 | -0.77 | -0.74 | -0.74 |
| Difference | -11.82 | 0.04 | 0 | 0.05 |
| Surprise % | -2,626.67% | 4.94% | 0.45% | 5.73% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.75 | -0.79 | -3.24 | -3.23 |
| 7 Days Ago | -0.77 | -0.81 | -3.39 | -3.77 |
| 30 Days Ago | -0.77 | -0.81 | -3.39 | -3.77 |
| 60 Days Ago | -0.77 | -0.81 | -3.39 | -3.77 |
| 90 Days Ago | -0.77 | -0.81 | -3.39 | -3.77 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | 1 | 1 | -- | 1 |
| Down Last 30 Days | -- | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BOLD | 93.91% | -2.60% | 15.93% | 0.31% |
| S&P 500 | 6.69% | 6.80% | 9.98% | 14.34% |
Upgrades & Downgrades
| Downgrade | Guggenheim: Buy to Neutral | 12/13/2024 |
| Initiated | Leerink Partners: Outperform | 4/22/2024 |
| Initiated | Guggenheim: Buy | 4/22/2024 |
| Initiated | Piper Sandler: Overweight | 4/22/2024 |
Related Tickers
CTNM Contineum Therapeutics, Inc.
6.13
-9.59%
KYTX Kyverna Therapeutics, Inc.
1.9700
-8.37%
PMVP PMV Pharmaceuticals, Inc.
0.9950
-0.50%
MAZE Maze Therapeutics, Inc.
9.32
-10.13%
ARTV Artiva Biotherapeutics, Inc.
2.5400
-11.19%
RAPP Rapport Therapeutics, Inc.
8.52
-14.46%
SEPN Septerna, Inc.
5.80
+5.55%
MBX MBX Biosciences, Inc.
6.37
-8.61%
SEER Seer, Inc.
1.6600
-1.78%
ZURA Zura Bio Limited
1.0850
-7.26%